Ivacaftor

Brand name: Kalydeco, Trikafta

DILI Likelihood

Score B — Known Hepatotoxin

This drug is known or highly likely to cause idiosyncratic liver injury and has a characteristic signature.

Between 12 and 50 cases including small case series have been described in the medical literature.

Classification

Primary class Genetic

Secondary class Cystic Fibrosis

FDA approval 2012